📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Tempus AI to Acquire Personalis

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Tempus AI to Acquire Personalis in $𝟏.𝟓 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 Deal - $Tempus AI(TEM.US) $Personalis(PSNL.US)

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐓𝐞𝐦𝐩𝐮𝐬 𝐀𝐈 will acquire 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬 in a $𝟏.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 transaction.

➤ Personalis shareholders will receive $𝟏𝟔.𝟐𝟓 per common share.

➤ Acquisition expands Tempus' 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬 (𝐌𝐑𝐃) capabilities.

➤ Deal combines Personalis' MRD technology with Tempus' 𝐀𝐈 and multimodal data platform.

➤ Tempus says MRD represents a $𝟐𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 market opportunity.

➤ Companies have partnered since 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟑.

➤ Personalis' NeXT Personal® test offers 𝐮𝐥𝐭𝐫𝐚𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐞 cancer recurrence monitoring.

➤ Medicare currently covers the test in 𝐭𝐡𝐫𝐞𝐞 indications.

➤ Acquisition aims to expand personalized cancer monitoring and biomarker discovery.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭𝐬:

𝐄𝐫𝐢𝐜 𝐋𝐞𝐟𝐤𝐨𝐟𝐬𝐤𝐲, CEO of Tempus:

“MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs. Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."

𝐂𝐡𝐫𝐢𝐬 𝐇𝐚𝐥𝐥, CEO of Personalis:

“We believe this transaction represents an exciting next chapter for Personalis. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners. After conducting an exhaustive process, we are confident Tempus’ offer provides the most value to our shareholders and the fastest path to bringing Personalis’ industry-leading tests to patients suffering from cancer.”